Exploring The Haemagglutinin-neuraminidase Of Human Parainfluenza Virus
Funder
National Health and Medical Research Council
Funding Amount
$731,268.00
Summary
Respiratory diseases, for example croup, in children are caused in the main by human parainfluenza viruses (hPIVs). No vaccines or specific antiviral therapy against hPIV infections exist. This project targets an essential protein in the virus’ lifecycle. This project will produce compounds that block the protein’s function and may provide drug candidates for development. Furthermore the role of human host cell-associated carbohydrates in parainfluenza infection will be better understood.
Development Of A Novel And Highly Selective CDK4/6 Inhibitor For Treating Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,171,199.00
Summary
We have identified and patented novel drug molecules targeting enzymes namely CDKs 4 and 6, that are important for survival of cancer cells. The drugs are highly selective and potent against CDK4/6, well absorbed orally, and have attracted much interest from a pharmaceutical company. Further detailed work is needed to characterize fully their anti-cancer effects and toxicity, thereby securing a major investment from our commercial partner for drug development for treating cancers.